CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
ESSAIS TESTANT LE ROLE DU PACLITAXEL


Précédent Retour au menu principal  Suivant


référence

chimiothérapie

n

(stIV)

% RO

p

SM

p

Giaccone, 1998 (1)

I . Paclitaxel (175 mg/m² en 3h) + CDDP (80 mg/m²)

162

 

(97)

28

 

 

0,02

9,9m

 

 

NS

II. Etoposide+ CDDP (80 mg/m²)

155

(98)

41

9,7m

Perry,

2000 (2)

I. PAC+Ifo

48

 

38

 

8,5 m

 

II. VNR+Ifo

45

 

31

7,4 m

Bonomi,

2000 (3)

I. CDDP + VP16

193

 

12

 

 

<0,001

7,6 m

 

 

0,09

II. CDDP + PAC (135mg/m2)

190

 

25

9,5 m

III.CDDP + PAC (250mg/m2)

191

 

28

10 m

Kosmidis,

2000 (4)

Carboplatin (AUC 6) +

 

 

 

 

 

0,73

 

 

 

0,35

I. PAC (175 mg/m2)

99

 

26%

9,5m

II. PAC (225 mg/m2)

94

 

32%

11,4m

Kelly,

2001 (5)

I.CDDP (100 mg/m²)  + VNR

202

 

28%

 

NS

8,1 m

 

NS

II.Carboplatine (AUC 6) + paclitaxel (225)

206

 

26%

8,6 m

Schiller,

2002 (6)

I.CDDP (75 mg/m²)+ paclitaxel (135 mg/m²)

303

89%

21%

 

 

 

NS

7,8 m

 

 

 

NS

II.CDDP 100 + gemcitabine

301

86%

22%

8,1 m

III.CDDP 75 + docetaxel (75 mg/m²)

304

86%

17%

7,4 m

IV.Carboplatine  (AUC 6) + paclitaxel (225)

299

86%

17%

8,1 m

Kosmidis,

2002 (7)

I. Paclitaxel (200 mg/m²) + Carbo (AUC 6)

252

(158)

28

 

0,12

10,4 m

 

0,32

II. Paclitaxel (200 mg/m²) + gemcitabine

257

(148)

35

9,8 m

Scagliotti,

2002 (8)

I. CDDP (75 mg/m²) + gemcitabine

205

81%

30

 


NS

9,8 m

 

 

NS

II. Carboplatine (AUC 6) + paclitaxel (225)

201

82%

32

9,9 m

III. CDDP (100 mg/m²) + VNR

201

81%

30

9,5 m

Greco,

2002 (9)

I. CBDCA (AUC 5)+paclitaxel (200)+ gemci

71

(51)

37

 

 

 

NS

9,2 m

 

 

 

NS

II. CBDCA (AUC 6)+paclitaxel (200)+ VNR

65

(51)

45

8,6 m

III. paclitaxel (200)+ gemci

64

(53)

32

8,7 m

IV. Gemci + VNR

67

(49)

33

10,7 m

Chen,

2002 (10)

I. Carboplatine (AUC 7) + paclitaxel (175)

45

 

40

 

14,1 m

 

II. paclitaxel (175)+ gemci

45

 

40

12,6 m

Belani,

2003 (11)

Carboplatine + paclitaxel

 

 

 

 

 

0,04

 

 

 

 

NS

I. AUC 6 / 4 sem – 100 mg/m² J1,8,15/4 sem

132

77%

32

41 s

II. (AUC 2 - 100 mg/m²) J1,8,15/4 sem

130

77%

24

31 s

III. (AUC 2 – 150~100 mg/m²) x6 / 8 sem

128

75%

18

40 s

Comella,

2004(12)

I. Gemcitabine + paclitaxel

65

(40)

32

 

 

 

0,01

9,2 m

 

 

 

NS

II. Gemcitabine + vinorelbine

68

(40)

23

9,7 m

III. Paclitaxel

63

(47)

13

6,4 m

IV. Gemcitabine

68

(44)

18

5,1 m

Belani,

2005 (13)

I. CDDP (75) + VP16

179

79 %

15 %

0,06

274 j

0,08

II. Carbo (AUC 6) + paclitaxel

190

77 %

23 %

233 j

Socinski,

2006 (14)

I. Carbo (AUC 6) + paclitaxel (225 mg/m²/3 sem)

81

88 %

32 %

 

6,6 m

 

II. Carbo (AUC 6) + paclitaxel (75 mg/m²/sem)

80

88 %

35 %

 

8,7 m

 

Belani,

2007 (15)

I. Gemci + paclitaxel hebdomadaire (100)

51

83 %

27 %

NS

10,3 m

NS

II. Gemci + paclitaxel ttes les 3 sem (200)

52

78 %

28 %

7,9 m

Langer,

2008 (16) I

I. Carbo (AUC 6) + paclitaxel poliglumex (210)

199

73 %

20 %

S

237 j

NS

II. Carbo (AUC 6) + paclitaxel poliglumex (225)

201

73 %

37 %

239 j

O’Brien,

2008 (17) I

PS 2

I. Paclitaxel  poliglumex (175)

191

68 %

11 %

 

220 j

NS

II. Gemci ou vinorelbine

190

68 %

15 %

198 j

Okamoto,

2010 (18)

I. Oral S-1 + carboplatine

282

76 %

 

 

13,2 m

NS

II. Paclitaxel + carboplatine

281

76 %

 

15,2 m

Kosmidis,

2011 (19)

I. Paclitaxel (200) + gemci (2 x 1)

196

91 %

27,5 %

NS

11,1 m

NS

II. Paclitaxel (200) + vinorelbine (22,5 x 3)

202

94 %

24 %

8,6 m

Socinski,

2012 (20) I

I. Nab-paclitaxel + carbo

521

79 %

33 %

S

12,1 m

NS

II. Paclitaxel + carbo

531

79 %

25 %

11,2 m


Références

(1) Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998 Jun;16(6):2133-41.
(2) Perry MC, Ihde DC, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN, et al. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer 2000 Apr;28(1):63-8.
(3) Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an eastern cooperative oncology group trial [In Process Citation]. J Clin Oncol 2000 Feb;18(3):623.
(4) Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C, et al. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000 Jul;11(7):799-805.
(5) Kelly K, Crowley J, Bunn PA, Jr., Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001 Jul 1;19(13):3210-8.
(6) Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 Jan 10;346(2):92-8.
(7) Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002 Sep 1;20(17):3578-85.
(8) Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2002 Nov 1;20(21):4285-91.
(9) Greco FA, Gray JR, Jr., Thompson DS, Burris HA, III, Erland JB, Barton JH, Jr., et al. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial. Cancer 2002 Sep 15;95(6):1279-85.
(10) Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM, et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 2002 Jan;13(1):108-15.
(11) Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003 Aug 1;21(15):2933-9.
(12) Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G, et al. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004 Aug 2;91(3):489-97.
(13) Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005 Jul;16(7):1069-75.
(14) Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 2006 Jan;17(1):104-9.
(15) Belani C, Dakhil S, Waterhouse D, Desch C, Rooney D, Clark R, et al. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 2007 Jan;18(1):110-5.
(16) Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008 Jun;3(6):623-30.
(17) O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008 Jul;3(7):728-34.
(18) Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 2010 Dec 20;28(36):5240-6.
(19) Kosmidis PA, Fountzilas G, Eleftheraki AG, Kalofonos HP, Pentheroudakis G, Skarlos D, et al. Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2011 Apr;22(4):827-34
(20) Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. J Clin Oncol 2012 Jun 10;30(17):2055-62.



Retour au début de la page